Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer

Inclusion Criteria:

1. Adult patients greater than 18 years of age.
2. ECOG performance status of 0, 1 or 2.
3. Patients with pathologically documented bulky T2, III and IV SCCHN (excluding M1 disease), within 2 months of diagnosis. Bulky T2 tumors are defined as those that have a volume of disease greater than 35 cm3 as measured by CT or MRI scan (28).
4. Patients will be medically fit for undergoing chemotherapy. Specifically:

   1. no evidence of active angina pectoris or ventricular arrhythmia's; no myocardial infarction within the last six months. (Patients with medically controlled hypertension or congestive heart failure are eligible.)
   2. an absolute neutrophil count of \> 1000/uL and platelet count \> 100,000/uL
   3. serum total bilirubin \< 1.5 mg/dL
   4. Creatinine Clearance greater than 60 ml/min

      Using an actual or calculated creatinine clearance using the formula:

      (140 - age)x(wgt in kg)\*/(serum creatinine)x(72)\* multiply by 0.85 for females
   5. if a pre-existing grade I neuropathy exists, patients must be willing to risk worsening neuropathy secondary to Paclitaxel. Patients with grade II or greater neuropathy will be excluded from study.
   6. ability to give written, informed consent to participate in the trial.
5. Patients will have measurable disease as determined by MRI or CT scan or evaluable disease determined by panendoscopy or indirect laryngoscopy to be eligible for enrollment on this study.

Exclusion Criteria:

1. Pregnant females. Males and women of childbearing potential must use effective contraception in order to prevent pregnancy during therapy.
2. Patients with a history of previous or current malignancy at other sites diagnosed within the last 5 years, with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin. Patients with a history of other malignancies, who remain free of recurrence or metastases for greater than five years are eligible.
3. Patients with active infection will not be eligible for this protocol until the infection is treated and the symptoms have clinically resolved.
4. Patients with a history of allergy to drugs utilizing Cremophor in the formulation.
5. Prior chemotherapy, prior irradiation or surgery for SCCHN will not be allowed.
6. Patients with metastatic disease will not be eligible for this study.
7. Patients with grade II or greater peripheral neuropathy will be excluded from study.